ARCTURUS THERAPEUTICS INC.

Company Overview

Arcturus Therapeutics Inc. is focused on mRNA medicines and vaccines. Its enabling technologies include lipid-mediated delivery (LUNAR), STARR mRNA technology (sa-mRNA), and expertise in mRNA drug substances and product manufacturing. The company has developed KOSTAIVE, which it claims is the first licensed self-amplifying messenger RNA (sa-mRNA) COVID vaccine. It has a joint venture in Japan called Arcalis, which is dedicated to producing mRNA vaccines and treatments, and maintains a global partnership with CSL Seqirus to develop new mRNA vaccines. Its pipeline features mRNA vaccine programs for influenza and SARS-CoV-2 (COVID-19), along with RNA therapeutic candidates intended for treating ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF) with over 500 patents and patent applications in the US, Europe, Japan, China, and other countries.

Financial Highlights (FY 2025)

Company's Business Segments

• RNA Therapeutics : The company offers late-stage RNA and mRNA rare therapeutics and vaccines for the treatment of rare diseases such as ornithine transcarbamylase deficiency and respiratory diseases.